The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection?

Journal Article (Review)

Transplantation therapies have revolutionized care for patients with endstage organ (kidney, liver, heart, lung, and pancreatic beta-cell) failure, yet significant problems persist with treatments designed to prevent graft rejection. Antirejection therapies are not always effective, must be taken daily, and are both expensive and associated with well-known toxic effects. Recent advances have suggested that the immune system has more self-regulatory capability than previously appreciated. In this review, we discuss immune system function and new therapeutic agents that modify so-called costimulatory receptor signaling to support transplant function without generally suppressing the immune system.

Full Text

Duke Authors

Cited Authors

  • Harlan, DM; Kirk, AD

Published Date

  • September 15, 1999

Published In

Volume / Issue

  • 282 / 11

Start / End Page

  • 1076 - 1082

PubMed ID

  • 10493208

Pubmed Central ID

  • 10493208

International Standard Serial Number (ISSN)

  • 0098-7484

Digital Object Identifier (DOI)

  • 10.1001/jama.282.11.1076

Language

  • eng

Conference Location

  • United States